Evidence map›Paper›PMID 39549258›Full record

ArticleTransplant infectious disease : an official journal of the Transplantation Society

Impact of Bebtelovimab Treatment Timing on COVID-19 Outcomes in Ambulatory Solid Organ Transplant Recipients.

Sonsoles Salto-Alejandre, Willa Cochran, Zishan Siddiqui, Julie Langlee, Lauren Boyer, Kristin Freed, Sophia Purekal, Ishaan Gupta, Mary Grace Bowring, Daniel C Brennan and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sonsoles Salto-AlejandreDivision of Infectious Diseases, Johns Hopkins University, Baltimore, USA.ORCID https://orcid.org/0000-0002-1280-4810
Willa CochranComprehensive Transplant Center, Baltimore, USA.
Zishan SiddiquiSchool of Medicine, Johns Hopkins University, Baltimore, USA.ORCID https://orcid.org/0000-0002-8790-5958
Julie LangleeComprehensive Transplant Center, Baltimore, USA.ORCID https://orcid.org/0000-0001-7424-7063
Lauren BoyerComprehensive Transplant Center, Baltimore, USA.
Kristin FreedComprehensive Transplant Center, Baltimore, USA.
Sophia PurekalSchool of Medicine, Johns Hopkins University, Baltimore, USA.
Ishaan GuptaSchool of Medicine, Johns Hopkins University, Baltimore, USA.ORCID https://orcid.org/0000-0003-2450-0029
Mary Grace BowringSchool of Medicine, Johns Hopkins University, Baltimore, USA.ORCID https://orcid.org/0000-0002-7299-7730
Daniel C BrennanComprehensive Transplant Center, Baltimore, USA.ORCID https://orcid.org/0000-0002-4818-7455
William WerbelDivision of Infectious Diseases, Johns Hopkins University, Baltimore, USA.ORCID https://orcid.org/0000-0003-2943-5895
Robin K AveryDivision of Infectious Diseases, Johns Hopkins University, Baltimore, USA.ORCID https://orcid.org/0000-0001-7692-3619

Funding

Leveraging a novel health records platform to predict the development of cardiovascular disease following kidney transplantationF30HL168842 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BOWRING, MARY GRACE · 2023 to 2025
$170k
Fulbright Grant 2022-2023 to Sonsoles Salto-AlejandreIMFAHE-University Excellence Fellowship 2021 to Sonsoles Salto-AlejandreNHLBI NIH HHS F30 HL168842NHLBI to Mary Grace Bowring F30 HL168842-01
6 · The paper itself

Abstract

backgroundOutcomes after bebtelovimab treatment for COVID-19 were favorable for most but not all solid organ transplant recipients (SOTRs) during the era of Omicron BA.2 to BA.5, but effects of timing of bebtelovimab administration on these outcomes are unknown. We sought to compare outcomes of SOTR who received early bebtelovimab ("EBT", given ≤ 2 days from diagnosis) versus late bebtelovimab ("LBT", given between Days 3 and 7), versus no bebtelovimab (NBT).

methodsThis was a retrospective cohort study of SOTRs with mild-to-moderate COVID-19, with endpoint of 30-day COVID-19-related hospitalization. Multivariable logistic regression was performed to determine variables associated with receiving EBT, and to assess impact of EBT on hospitalization. A propensity score (PS) was calculated for EBT versus NBT.

resultsOf 297 SOTRs, 162 (58.1%) received EBT, 46 (16.5%) LBT, and 71 (25.4%) NBT. Early bebtelovimab treatment was associated with a lower risk of 30-day COVID-19-related hospitalization compared to NBT (OR, 0.112 [95% CI, 0.018-0.686]; p = 0.018). There was no significant difference in hospitalization risk between LBT and NBT, suggesting that delayed administration may not confer additional benefits over no treatment.

conclusionsEarly bebtelovimab treatment in outpatient SOTRs was associated with a lower risk of hospitalization compared to no treatment, while late administration did not show a significant advantage over no treatment. Although bebtelovimab is no longer authorized, these findings suggest that the timing of COVID therapies for SOTRs may be important to optimize outcomes.

Indexed as

COVID-19COVID-19 Drug TreatmentOrgan TransplantationTransplant RecipientsAdultAgedFemaleHospitalizationHumansMaleMiddle AgedRetrospective StudiesSARS-CoV-2Time FactorsTreatment OutcomebebtelovimabCOVID‐19COVID‐19 treatmenthospitalizationOmicronSARS‐CoV‐2solid organ transplant

Identifiers

PMID39549258
PMCPMC11827732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.